Vyome Reports Sharp Reduction in Q3 2026 Loss Per Share; Advances Lead VT-1953 Program
Vyome Holdings, Inc. (NASDAQ:HIND, “Vyome” or the “Company”), a clinical-stage biopharmaceutical company focused on immuno-inflammatory and rare disease conditions, reported financial results for the third quarter ended September 30, 2026, and provided a corporate update.Krishna Gupta, Chairman of…